Corporate Presentation - Aussie Equities Day 2022
Released
Released
Announcement PDF
Corporate Presentation
Aussie Equities Day 2022
July 2022
Disclaimer
DISCLAIMER
This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any
potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal,
taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information,
statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any
estimates, forecasts or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs,
financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including
pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or
any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to
the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all
available information and should not be used in isolation as a basis to invest in the Company.
FUTURE MATTERS
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.
Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by
known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or
implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will
be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue
reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or
intended.
US DISCLOSURE
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S
under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United
States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.
1
Management Structure
Dr John Prendergast – Chairman
James Graham – Chief Executive Officer
Michele Dilizia – Chief Scientific Officer
US based, current Chairman and Co-founder
of Palatin Technologies, Inc. (NYSE: PTN) and
Lead Director of Heat Biologics, Inc.
(NASDAQ: HTBX) – extensive experience in
the international commercialisation of
pharmaceutical technologies.
5 years as former Executive Director at
RCE. Invested alongside shareholders in
most capital rounds since inception.
Background in marketing, business
development and commercialisation of
early-stage technologies.
Co-inventor and qualified medical scientist;
specialisation in medical microbiology and
regulatory affairs requirements.
BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)
BCom (Entrepreneurship), GAICD
BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM
2
A Versatile Technology Platform
R529
• Biotech company developing Anti-infectives targeting
both bacterial and viral indications
• Strong IP and own manufacturing capability
• Qualified Infectious Disease Product designation
• 10 years market exclusivity plus fast track approval*
• Versatile delivery platform – oral, intravenous and topical
R327
formulations
• Designed to safely provide treatment without developing
resistance over time
• Multiple infectious disease opportunities with RECCE® 327
R435
*Awarded by the US FDA in 2017 for R327 bacteraemia (broad-spectrum bacterial sepsis). Time starts only from potential market approval.
Strong Pipeline
Over Various Indications and Upcoming Inflection Points
Asset
Indications
Discovery
Preclinical
Phase I
Phase II
Phase III
Anti-bacterial programs Indication
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Route of administration
Market Size
Market Size
EU/US/AU
Serious/life threatening
bacterial infections
including sepsis
47-50 million cases
worldwide.
R327
Wound infections
including infected burns
11 million burn
wound cases
requiring medical
intervention.
Majority of which
escalate to infection.
RCE
Multiple ongoing
pre-clinical programs
-
R327
COVID & Influenza
-
R529
COVID
-
R327
Intravenous
Topical
Compounds
Anti-viral programs
Nasal
IV and Intranasal
4
Sepsis – it’s a big problem!
48.9 million incident
cases of sepsis
recorded worldwide1
11 million sepsisrelated deaths recorded2
One in three patients
who die in hospital
have sepsis3
• Sepsis is a life-threatening inflammatory response to infection that has spread in the body.
• Kills more people in the US than prostate, breast cancer and HIV/AIDS combined4.
• Is the most expensive condition to treat in the last 8 years5.
• Double the average cost per stay across all other conditions5.
• Currently no drug therapies specifically for the treatment of sepsis6.
1,2,3 – The Lancet
4 – BioMed Central
5 – University of Texas
6 – International Medicine Journal RACP
5
Sepsis Treatment Paradigm
Impact of delayed antibiotic
treatment on odds ratio for mortality1
• Current treatment paradigm relies on:
• Introducing broad-spectrum antibiotic(s)
• Running antibiograms
• Adjusting antibiotics based on
antibiogram results
Early treatment with the correct
antibiotic is key to improving patient outcome
~1/3 of patients present unspecific symptoms, leading
to delayed treatment and high mortality rate
Mortality from sepsis increases by as much as
8% for every hour that treatment is delayed2
1 – Vincent X. Liu et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis - Am J Respir Crit Care Med. 2017 Oct 1; 196(7): 856–863. 6
2 – https://www.sepsis.org/wp-content/uploads/2017/05/Sepsis-Fact-Sheet-2018.pdf
Natural Antibiotics vs Synthetic Anti-Infectives
• Pre-formed natural superbugs.
• All Fungi or Bacteria based
• “Penicillin allergy is the most common drug allergy and is reported in up to 15 percent of
hospitalized patients” 1
• Only as good as what’s found in nature.
Natural Antibiotics
• Has always had naturally occurring superbugs, now multiplying out of control!
• NO pre-formed natural superbugs.
• Entirely man-made and designed with purpose.
• Universal Mechanism of Action - detailed experimentation demonstrates it does not succumb to
superbugs.
• Contains only what we want - not reliant on what’s found in nature.
Synthetic Anti-Infective
• Broad-spectrum capability and maintains its activity even with repeated use!
1- Lee, C E et al. “The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance.” Archives
of internal medicine vol. 160,18 (2000): 2819-22. doi:10.1001/archinte.160.18.2819
Independent Study Undertaken on R327 MoA1
327
435
529
By Leading Experts in Bacterial MoA Analysis
Stage 2
Stage 1
R327 interrupts bacterial cellular energetics via ATP Synthesis
R327 permeabilizes cell membrane and enters the cell
Stage 4
Stage 3
Cellular division & non-dividing cell functions are disrupted
R327 is rapidly and irreversibly bactericidal - at high concentrations causes cell lysis
1 – Dilizia, M., Tsunemoto, H., Quach, D. et al. Elucidating the Mechanism of Action of Novel Polymer-based Synthetic Anti-infective Compound RECCE 327 - Abstract
RECCE® 327 Multi-Layered Mechanism of Action1
327
435
529
R327 rapidly & irreversibly
shuts down cellular energetics
(adenosine triphosphate (ATP)
production) – primary MoA.
R327 affects the assembly of
bacterial cell division complex,
components that require cellular
energy to remain assembled,
confirming its ability to disrupt
cellular bioenergetics.
R327 results in the
decreased formation of the
bacterial cell division
complex into ring-like
structures (Z-rings) in a
concentration dependent
manner.
R327 permeabilises the cell
membrane/alters the integrity
of the outer membrane of E. coli
cells – intended activity without
toxicity.
At higher concentrations and
subsequent to ATP shut down
cell lysis can occur as a further
MoA (bacterial bursting due to
their uniquely high internal
pressure).
R327 rapidly and irreversibly
bactericidal to slow-growing
quiescent or stationary phase
E. coli cells in addition to
actively dividing E. coli cells.
Within a minute, the highest
concentration of R327 used, 5x
MIC, was observed to reduce
viable cell counts reported as cell
forming units per millilitre of culture
(CFU/ml) 100-fold (>1x107 to 1x105
at timepoint 0).
Current antibiotics rarely retain
bactericidal activities against
non-dividing or stationary phase
bacterial cells; however, R327
showed remarkable activity against
slow-growing bacteria, indicating
potential antibacterial activity in
biofilms.
In comparison to ampicillin and
ciprofloxacin, R327 is able to
outperform both of these
antibiotics in bactericidal activity
(measured by viable cell counts)
against stationary cells.
1 – Dilizia, M., Tsunemoto, H., Quach, D. et al. Elucidating the Mechanism of Action of Novel Polymer-based Synthetic Anti-infective Compound RECCE 327 - Abstract
RECCE® 327 Activity Against Escherichia coli
• E. coli grows fast.
Eukaryotic cells growing
healthy, not affected.
Without R327
R327 (3,000 ppm)
• R327 at 3,000 ppm shown
to be highly effective against
E. coli without affecting
growing, healthy eukaryotic
cells.
• R327 rapidly and irreversibly
shuts down the ATP in
E. coli, not allowing it to
divide and grow.
eukaryotic cells
E. coli
RECCE® 327 Activity Against Staphylococcus aureus
• S. aureus bacterial growth
slower than E. coli, not
affecting eukaryotic cells.
Without R327
R327 (2,300 ppm)
• R327 at 2,300 ppm shows to
be highly effective against
S. aureus without affecting
growing, healthy eukaryotic
cells.
• R327 rapidly and irreversibly
shuts down the ATP in
S. aureus, not allowing it to
divide and grow.
eukaryotic cells
S. aureus
Phase I Human Clinical Trial
120x dose amount*
•
Study to assess IV infusion of RECCE® 327
in 80 healthy male subjects as a single
ascending dose.
•
Randomized, double-blind, placebo-controlled,
safety, tolerability and pharmacokinetics study.
•
Single dose of a 1-hour via IV infusion at a
uniform rate in hospital setting.
•
Primary endpoint: vital signs, 12-lead ECG
parameters, clinical chemistry, hematology, and
urinalysis.
High Dose
7-10 subjects in each
cohort: 2 control, 8 R327
Low Dose
36 subjects successfully
dosed across Cohorts 1-4
*Dose increase fold based off 50mg
6,000 mg (& beyond?)
80x dose amount*
4,000 mg ✓
40x dose amount*
2,000 mg ✓
20x dose amount*
1,000 mg ✓
10x dose amount*
500 mg ✓
3x dose amount*
150 mg ✓
1x dose amount
50 mg ✓
Phase I Human Clinical Trial – ‘High Dose’
Why 6,000mg (R327) over 1 hour infusion?
120x dose amount*
High Dose
7-10 subjects in each
cohort: 2 control, 8 R327
6,000 mg
(& beyond?)
• Study objectives broadly achieved – now ‘dose-ceiling’ focused.
• 6,000mg (6 grams) over 1 hour IV is HIGH (double the jump
between prior two cohorts).
80x dose amount*
• R327 dosing broadly in efficacy range based on animal models –
Phase II (efficacy) to determine.
4,000 mg ✓
• Phase I (IV Safety/Tolerability) data sets opportunity for multiple
Phase II (efficacy) study potential (need not repeat the now known).
• Next Phase preparations well underway (these now dose escalation increments
welcomed bonus data sets).
40x dose amount*
2,000 mg ✓
*Dose increase fold based off 50mg
Topical RECCE® 327 - Phase I/II
Burn wound infections
20 patients – dosing 3 times/week
for 2 weeks duration
• Phase I/II to assess Topical RECCE® 327 in
burn wound infections commenced in Q4 2021.
• Sponsored by the South Metropolitan Health
Service, Department of Health, Government of
Western Australia.
Primary outcome at
14 days post dosing
• Multiple patients have been dosed with R327.
• Trial Investigators:
• Dr Edward Raby (Clinical Microbiologist and
Infectious Diseases expert at Royal Perth and
Fiona Stanley Hospitals).
30
patients
Infection
status
of wound1
• Professor Fiona Wood (Head of Burns) –
world-renowned burns specialist and spray-on
skin pioneer.
• Dr Chris Heath (Head of Infectious Diseases).
10 patients – daily dosing for 2 weeks duration
1 - Using the consensus clinical criteria of the International Wound Infection Institute
Topical RECCE® 327 – Phase I/II
Patient examples from ongoing Burn Wound trial
• Patients suffered major burn injury.
• Multiple bacterial species in and surrounding wound.
• Growth swabs with organisms including pathogens from the
ESKAPE group of bacteria.
• Post R327 treatment: healthy skin growth return, reduced
swelling and infection, indications of tissue penetration to
underlying infection.
Study data now under-review for next-step considerations.
Pre-treatment, significant
bacterial infection
Post R327 treatment
Patents
Three families across all major markets
Recce’s patent portfolio includes more than 20 issued patents
and patent applications in the world’s major markets, including
the United States, Europe, Japan, China and Australia.
Filed
Australia
USA
Europe
Japan
China
✓ Granted
Patent
Family 1
Expiry
Patent
Family 2
Expiry
Patent
Family 3
Expiry
✓
2028
✓
2035
Pending
2037
2035
✓
2037
✓
✓
✓
✓
2029
2028
✓
✓
2035
2028
✓
2035
2028
Pending
2035
✓
✓
✓
2037
2037
2037
Patent Family 1 – Antimicrobial Polymers and
their Compositions
Family 1 group relates to the Company’s
unique and highly economical manufacturing
process and use of the polymer in treatment
of diseases.
Patent Family 2 – Copolymer for use in
Method of Treatment of a Parenteral Infection
Family 2 relates to the method of
manufacture, administration and application to
treat a broad range of common human
infections.
Patent Family 3 – Anti-Virus Agent and
Method for Treatment of Viral Infection
Family 3 relates to a method of treatment of a
broad range of viral infections, particularly
parenteral viral infection.
Insourced Manufacturing Capabilities
Wholly owned, automated manufacturing
facility in Sydney’s Macquarie Park
• Raw materials plentiful and cheap – few $/Kg
• No expensive waste – 99.9% product yield
• Automated manufacture process taking
approximately 1 hour
• 500 doses per fully automated run
• Currently producing in volumes to support
planned Phase I & II clinical trials.
• Facility built to pharmaceutical specification.
• Packaging and labelling to international
‘tamper-proof’ standards
Recce Pharmaceuticals Ltd – Capital Structure
7%
Snapshot
Tickers
ASX:RCE, FSE:R9Q
Market Cap (approx.)
AUD $156 million
Cash and deposits
AUD $15.8 million
Outstanding shares
177.65 million
Average daily volume
150.97k
Debt
Nil
Priced at $0.88
31 March 2022
3 months
27%
Top 20
Shareholder Distribution
58%
8%
RCE
recce.com.au
Institution
Retail
Other
17
Investment Summary
Proprietary new class of anti-infectives against bacteria and viruses, protected by Composition of Matter Patent.
Fast development plans initially targeting: Sepsis, Burn wounds, Helicobacter pylori and COVID-19.
Strong pre-clinical data package demonstrating high bactericidal activity combined with very good safety at
expected human therapeutic range.
State of the Art manufacturing capacities ensuring highly attractive manufacturing costs and scalability.
R327 Phase I clinical trial – Subjects in Cohorts 1-6 dosed delivering further interim data imminent.
Topical Phase I/II human clinical study of R327 commenced Q4 2021; further interim data imminent.
Robust financial position to deliver clinical data.
Thank you
James Graham
Managing Director and Chief Executive Officer
Recce Pharmaceuticals Ltd
ASX:RCE; FSE:R9Q
+61 2 9256 2572
james.graham@recce.com.au
recce.com.au
Share your feedback
Discover